The EMIRATES Study
Launched by ROYAL MARSDEN NHS FOUNDATION TRUST · Feb 27, 2025
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
The EMIRATES Study is a clinical trial designed to help patients with differentiated thyroid cancer (DTC) make informed decisions about their surgical treatment options. In this study, patients will participate in two outpatient consultations. First, they will receive standard care without any additional resources. Then, in the second part of the study, they will use a special Patient Decision Aid (PDA) pamphlet that provides clear information about their condition and treatment choices. This pamphlet aims to help them understand their options better so they can have a shared decision-making experience with their healthcare team regarding whether to undergo a hemithyroidectomy (removal of part of the thyroid) or a total thyroidectomy (removal of the entire thyroid).
To participate in this study, you need to be over 18 years old and diagnosed with low-risk well-differentiated thyroid cancer, such as papillary or follicular carcinoma, that is between 1-4 cm in size. You must also be able to communicate in English. Throughout the trial, participants will complete questionnaires to share how confident they feel about their treatment decisions and their overall satisfaction. This study is currently recruiting participants, and it provides a valuable opportunity to contribute to better decision-making support for future patients with thyroid cancer.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Aged over 18
- • Both genders
- * Patients who are diagnosed of low-risk well-differentiated thyroid carcinoma (papillary thyroid carcinoma or follicular carcinoma) with size of 1-4cm. This is either:
- • 1. Diagnosed pre-operatively by fine-needle aspiration cytology (FNAC) with Thy5 grade \[see appendix for the Thy classification\] or
- • 2. Confirmed following diagnostic hemithyroidectomy
- • Able to communicate in spoken and written English
- Exclusion Criteria:
- • Patients who are diagnosed with thyroid cancer with adverse features (i.e. poor differentiated cytology or tall cell, columnar cell, Hurthle cell, and solid variant cytology)
- • Patients who are diagnosed with thyroid cancer which is multifocal, bilateral, with extrathyroidal extension, with perineural invasion or angioinvasion.
- • Patients who are diagnosed with thyroid cancer with clinically or radiologically involved nodes or distant metastases
- • Patients who are diagnosed with thyroid cancer which is of a familial disease
- • Patient who is either Pregnant or breast-feeding
- • Patient with hyper- or hypothyroidism who is a candidate for surgery
- • Patient who is concurrently diagnosed with any medullary, anaplastic, lymphoma, or parathyroid disease
- • Patients who had previous thyroidectomy for reasons other than diagnostic hemithyroidectomy for their recent cancer diagnosis.
- • Patients who are cognitively impaired or have a mental health condition and are therefore unable to give consent
- • Patient who is not able to read write and speak English
About Royal Marsden Nhs Foundation Trust
The Royal Marsden NHS Foundation Trust is a leading cancer treatment and research institution in the UK, renowned for its commitment to advancing oncology through innovative clinical trials and cutting-edge therapies. With a multidisciplinary team of experts, the Trust integrates patient care with groundbreaking research, fostering a collaborative environment to improve outcomes for cancer patients. As a pioneer in the field, the Royal Marsden actively contributes to the development of new treatment protocols and plays a critical role in translating scientific discoveries into clinical practice, ensuring that patients have access to the latest advancements in cancer care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Wigan, , United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported